Generative AI New Drug Development Company Absci Corporation announced on January 8 a partnership with AMD AMD has entered into a strategic partnership to deploy AMD Instinct gas pedals and ROCm software to support key AI new drug discovery workloads, including Absci's from-scratch antibody design models. AMD is also investing $20 million in Absci in the form of a Private Investment in Private Equity (PIPE) investment (I note: currently ~RMB147 million).
Absci says this demonstrates the growing need for innovative AI applications in the drug discovery space, and this partnership will help Absci realize its mission to create better biologics faster for patients by providing efficient AI solutions toAccelerating complex biological modeling, optimizing performance, reducing infrastructure costs, and shortening innovation cycles.
On January 15, Pacific Time, Absci and AMD will co-present the AMD Instinct Accelerator Excels in Tackling Complex Biology ApplicationsThese include Absci's first in vitro validated IgDesign1 model, which is also the world's first antibody-designed reverse folding model.
